carcinomatous myopathy

(redirected from Lambert-Eaton myasthenic syndrome)
Also found in: Thesaurus, Medical, Acronyms, Wikipedia.
Related to Lambert-Eaton myasthenic syndrome: myasthenia gravis
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.carcinomatous myopathy - a disease seen in patients with lung cancer and characterized by weakness and fatigue of hip and thigh muscles and an aching back; caused by antibodies directed against the neuromuscular junctions
disease of the neuromuscular junction - a disease characterized by impairment of neuromuscular junctions
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
Public health agency the US Food and Drug Administration announced on Monday that it has authorised Ruzurgi (amifampridine) tablets, which is the first and only treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients six to less than 17 years of age, under its priority review, orphan drug and fast track designations.
We had nine patients with PNS; two patients had subacute cerebellar degeneration (SCD); three had Stiff-person syndrome (SPS); one had Lambert-Eaton myasthenic syndrome (LEMS); and the remaining patient had sensory neuropathy (SN).
A specific example is the Lambert-Eaton myasthenic syndrome characterised by proximal muscular weakness that improves with continued use and hyporeflexia and dysautonomia.
Lambert-Eaton myasthenic syndrome (LEMS) is a rare neuromuscular junction disorder resulting from the development of auto-antibodies against voltage-gated calcium channels (VGCCs) in pre-synaptic terminals (1).
Lambert-Eaton myasthenic syndrome antibodies (voltage gate calcium channel (VGCC) antibodies) were also negative.
The Lambert-Eaton myasthenic syndrome is a disorder occurring in the setting of an underlying malignancy such as bronchus carcinoma.
The ultra-rare diseases category includes Duchenne's muscular dystrophy (DMD), molybdenum cofactor deficiency (MoDC) type A, lysosomal acid lipase (LAL) deficiency, sporadic inclusion body myositis (sIBM), epidermal bulbosa (EB), Lambert-Eaton myasthenic syndrome (LEMS) and hypothosphatasia.
Also last month Catalyst Pharmaceutical Partners received the designation for Firdapase to treat Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.